Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
21.22
+1.79 (9.21%)
Aug 7, 2025, 4:00 PM - Market closed

Company Description

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.

Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study.

The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses.

It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies.

The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.

Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Assembly Biosciences, Inc.
Assembly Biosciences logo
CountryUnited States
Founded2005
IPO DateDec 17, 2010
IndustryBiotechnology
SectorHealthcare
Employees73
CEOJason Okazaki

Contact Details

Address:
Two Tower Place, 7th Floor
South San Francisco, California 94080
United States
Phone833 509 4583
Websiteassemblybio.com

Stock Details

Ticker SymbolASMB
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001426800
CUSIP Number045396108
ISIN NumberUS0453962070
SIC Code2834

Key Executives

NamePosition
Jason A. Okazaki J.D.Chief Executive Officer, President and Director
Dr. William E. Delaney IV, Ph.D.Chief Scientific Officer
Dr. Nicole S. White Ph.D.Chief Manufacturing Officer
Jeanette M. BjorkquistPrincipal Financial Officer, Executive Director of Accounting and Treasury
Shannon RyanSenior Vice President of Investor Relations, Corporate Affairs and Alliance Management
Jennifer A. Troia MHROD, SHRM-SCP, SPHRChief Human Resources Officer
Dr. Anuj Gaggar M.D., Ph.D.Chief Medical Officer
Thomas E. RollinsExecutive Officer
Amy Figueroa C.F.A.Investor Relations Consultant

Latest SEC Filings

DateTypeTitle
Aug 7, 2025S-3MEFFiling
Aug 6, 2025S-8Securities to be offered to employees in employee benefit plans
Aug 6, 202510-QQuarterly Report
Aug 6, 20258-KCurrent Report
Jun 25, 20258-KCurrent Report
Jun 9, 20258-KCurrent Report
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 23, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 23, 2025DEF 14AOther definitive proxy statements